- £1.92bn
- £1.39bn
- $630.20m
- 18
- 10
- 54
- 14
REG - Hutchmed China Ltd - China Approval based on Phase III SACHI Trial
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementREG - Hutchmed China Ltd - Grant of Share Options and Awards under LTIP
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights SACHI Phase III Data at ASCO
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ASCO
AnnouncementREG - Hutchmed China Ltd - AGM held on May 13, 2025 – Poll Results
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED - Data to be Presented at AACR 2025
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Completes Enrollment of Phase II Study
AnnouncementREG - Hutchmed China Ltd - 2024 Annual Report and Notice of AGM
AnnouncementREG - Hutchmed China Ltd - Extraordinary General Meeting – Poll Results
AnnouncementRCS - Hutchmed China Ltd - NMPA Conditional Approval for TAZVERIK®
AnnouncementREG - Hutchmed China Ltd - Retirement of Independent Non-executive Directors
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Savolitinib SAVANNAH Phase II
AnnouncementRCS - Hutchmed China Ltd - Publication of Form 20-F
AnnouncementREG - Hutchmed China Ltd - 2024 Final Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - Phase II/III Study of Fruquintinib and Sintilimab
AnnouncementREG - Hutchmed China Ltd - Adoption of the 2025 Long Term Incentive Plan
Announcement